News EU regulators back J&J's Zytiga in early prostate cancer use New use could give J&J drug edge over Pfizer's rival
News Pfizer could fetch $15bn for consumer health business Pfizer is considering selling its consumer healthcare business in a deal that could be worth around $15 billion.
Partner Content Partner Content How to create an integrated social media and digital strateg... Social Media in Pharma
R&D SpringWorks spins out of Pfizer on rare disease mission A new biotech spun out of Pfizer is to develop four drugs for rare and serious diseases.
News FDA advisers split on new kidney cancer use for Pfizer's Sut... Committee could not decide if Sutent can be used after the removal of a cancerous kidney.
News Pfizer sues J&J, alleging it blocked access to Remicade bios... J&J used anticompetitive tactics to prevent use of cheaper Inflectra
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.